SCHEMBL4263133

SCHEMBL4263133

COC(=O)C(c1ccccc1)N(Cc1ccccc1)C(=O)c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CRHBP P24387 1/20 0.60
CRHR2 Q13324 1/20 0.60
TMEM97 Q5BJF2 2/20 0.49
SIGMAR1 Q99720 2/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
SMN1; SMN2 Q16637 3/20 0.47
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
ALDH1A1 P00352 3/20 0.47
LMNA P02545 2/20 0.47
TP53 P04637 1/20 0.47
MAPK1 P28482 1/20 0.46
TAAR1 Q96RJ0 1/20 0.44
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4254587 0.88 CRHBP (0.68) CRHBPCRHR2TMEM97SIGMAR1MEN1
SCHEMBL3456594 0.82 CRHBP (0.70) CRHBPCRHR2TMEM97SIGMAR1MEN1
SCHEMBL14066212 0.75 ITGA4 (0.48) MEN1KMT2AL3MBTL1SMN1; SMN2RAB9A
SCHEMBL7281801 0.73 MEN1 (0.52) CRHBPCRHR2TMEM97SIGMAR1MEN1
SCHEMBL3453497 0.72 CRHBP (0.70) CRHBPCRHR2TMEM97SIGMAR1MEN1
SCHEMBL2880324 0.72 KMT2A (0.57) MEN1KMT2AALDH1A1MAPT
SCHEMBL6799985 0.71 ITGA4 (0.51) CRHBPCRHR2MEN1KMT2ASMN1; SMN2
SCHEMBL6799990 0.71 ITGA4 (0.51) CRHBPCRHR2MEN1KMT2ASMN1; SMN2
SCHEMBL2456812 0.71 CRHBP (0.43) CRHBPCRHR2TMEM97SIGMAR1MEN1
SCHEMBL9081450 0.71 POLB (0.44) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8404722-B2 Oxazole compounds compositions and methods of use AMGEN INC. (US) 2013-03-26 US disclosed
US-8404722-B2 Oxazole compounds compositions and methods of use AMGEN INC. (US) 2013-03-26 US disclosed
US-20110060011-A1 OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE AMGEN INC. (US) 2011-03-10 US disclosed
US-20110060011-A1 OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE AMGEN INC. (US) 2011-03-10 US disclosed
WO-2009151495-A2 OXAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AMGEN INC. (US) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110060011-A1 OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE OXA1L, CYP11B2, CYP3A7 CRHBP 4664/4885CRHR2 2706/4885TMEM97 1022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.